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The control of cell fate is an epigenetic process initi-
ated by transcription factors (TFs) that recognize
DNAmotifs and recruit activator complexes and tran-
scriptional machineries to chromatin. Lineage speci-
ficity is thought to be provided solely by TF-motif
pairing, while the recruited activators are passive.
Here, we show that INTS13, a subunit of the Inte-
grator complex, operates as monocytic/macro-
phagic differentiation factor. Integrator is a general
activator of transcription at coding genes and is
required for eRNA maturation. Here, we show that
INTS13 functions as an independent sub-module
and targets enhancers through Early Growth
Response (EGR1/2) TFs and their co-factor NAB2.
INTS13 binds poised monocytic enhancers eliciting
chromatin looping and activation. Independent
depletion of INTS13, EGR1, or NAB2 impairs mono-
cytic differentiation of cell lines and primary human
progenitors. Our data demonstrate that Integrator is
not functionally homogeneous and has TF-specific
regulatory potential, revealing a new enhancer regu-
latory axis that controls myeloid differentiation.
INTRODUCTION
Cis-regulatory elements orchestrate spatial and temporal gene
expression in metazoans. Enhancers are essential during tissue
development and cell differentiation, such as in the hematopoi-
etic compartment (Álvarez-Errico et al., 2015; Heinz et al.,
2015; Huang et al., 2016). Precisely, recognition of DNA motifs
by a select combination of transcription factors (TFs) activates
enhancers that were otherwise repressed or in a poised/inactive
conformation (Heinz et al., 2010, 2015). While repressed en-
hancers lack DNA accessibility and are embedded in a repres-
sive chromatin conformation, poised enhancers are generallynucleosome-free to facilitate binding of lineage-determining
TFs to their respective DNAmotifs. Poised enhancers are devoid
of H3K27ac mark (enriched at enhancers that are active or
recently dismissed) but carry sustained levels of H3K4me1
(Creyghton et al., 2010; Rada-Iglesias et al., 2011). It is believed
that recruitment of TFs first leads to hyper-acetylation of nucle-
osomes surrounding the enhancer core (Whyte et al., 2013).
Next, TFs pair with the Mediator complex to recruit the
RNAPII holoenzyme and initiate bi-directional transcription of
enhancer-associated noncoding RNAs (eRNAs) (Li et al., 2013).
The Integrator, a large co-activator complex endowed with
RNA endonucleolytic activity, is required to terminate eRNA tran-
scripts and consequently allow their accumulation at chromatin.
eRNAs are implicated in enhancer activation, perhaps by enforc-
ing chromosomal looping between enhancers and their target
promoters (Hsieh et al., 2014; Lai et al., 2015). In addition, eRNAs
may function in maintenance of H3K27ac levels (Bose et al.,
2017), and in release of the paused RNAPII at target promoters
(Schaukowitch et al., 2014). The overall mechanistic process of
enhancer activation is not clear. For instance, the series of
events that bring inactive or poised enhancers to full activation
is poorly understood. Here, we present a novel function for a
component of the Integrator complex in activating lineage-spe-
cific enhancers.
Integrator is conserved acrossmetazoans and is composed of
14 subunits (INTS1–INTS14) (Baillat et al., 2005; Chen et al.,
2012). This protein complex associates with the C-terminal
domain of RNAPII and is implicated in the biogenesis of spliceo-
somal U small nuclear RNAs (snRNAs) (Baillat et al., 2005). In
fact, the endonucleolytic heterodimer INTS9/INTS11 cleaves
nascent U snRNA transcripts to initiate their maturation (Baillat
et al., 2005). Integrator’s activity at enhancers is also critical to
establish chromosomal looping with target promoters to drive
gene activation (Lai et al., 2015). Furthermore, Integrator is
loaded at the proximal promoter of protein-coding genes, where
it controls the release of paused RNAPII by recruiting the SEC/
pTEFb complex and modulating the activity of Negative Elonga-
tion Factor (NELF) (Gardini et al., 2014; Stadelmayer et al., 2014).
While the catalytic function and genomic distribution of the
INTS9/INTS11 heterodimer has been established, the remainingMolecular Cell 71, 103–116, July 5, 2018 ª 2018 Elsevier Inc. 103
12 subunits of the complex are largely uncharacterized. Here, we
describe that the INTS13 subunit has a lineage-specific role in
regulating enhancer activity. Our data indicate that INTS13 reg-
ulates enhancer regions bound by the EGR1/2 TFs, in associa-
tion with the co-factor NAB2, during differentiation of progenitor
cells into monocytes and macrophages.
In the myeloid branch of hematopoiesis, monocytes and mac-
rophages (the tissue-resident counterpart of monocytes) are
specialized phagocytic cells that rely on TFs such as SPI1,
CEBPa, and CEBPb as master determinants of commitment
and differentiation (Álvarez-Errico et al., 2015; Friedman, 2007;
Scott et al., 1994). Some of these TFs, such as SPI1, are also crit-
ical in regulating the activity of terminally differentiated macro-
phages (Barozzi et al., 2014; Heinz et al., 2010; Ostuni et al.,
2013). While the Early Growth Response (EGR) TFs have largely
been studied during neural development (Giudicelli et al., 2001;
Poirier et al., 2008; Thierion et al., 2017), EGR1/2 are also active
during myelopoiesis, promoting monocytic/macrophagic differ-
entiation in a variety of human cell lines as well as primary
myeloid precursors (Krishnaraju et al., 2001; Laslo et al., 2006;
Nguyen et al., 1993; Pham et al., 2012). Our data support a
fundamental role for EGR1/2 in monocytic commitment and
defines their activity at critical lineage-determining enhancers,
such as the enhancer of CSF1R. Furthermore, we identify
NAB2, previously suggested to be a repressor of EGR1 activity
(Kumbrink et al., 2010), as the fundamental co-activator of
monocytic enhancers in association with EGR1 and the Inte-
grator complex. In summary, we describe a network of en-
hancers driving differentiation via the Integrator/EGR/NAB2
axis and provide the first evidence that Integrator has modular
components, conferring lineage-specific activity to this evolu-
tionarily conserved complex.
RESULTS
Functional Dissection of the INTS11 and INTS13
Subunits of Integrator
Integrator targets active protein-coding genes, regulates the
release of paused RNAPII from proximal promoters (Gardini
et al., 2014; Stadelmayer et al., 2014; van den Berg et al.,
2017), andmodulates the biogenesis of noncoding eRNAs at en-
hancers through the endonucleolytic activity of the INTS11 sub-
unit (Lai et al., 2015). Unlike Mediator, Integrator is specific to
metazoans, suggesting that it may play a role in tissue and
cell-fate specification. To dissect the role of Integrator in gene
regulation, we examined the poorly characterized INTS13 sub-
unit, along with the core catalytic subunit INTS11, in the myeloid
HL-60 cell line.
First, we immunoprecipitated INTS13 from the nuclear extract
of HL-60 cells and found strong association with INTS11 and
INTS1, indicating that INTS13 is a bona fide component of Inte-
grator in myeloid cells (Figures 1A and 1B). Second, to begin
characterizing the role of INTS13 within the Integrator complex,
we assayed RNA endonucleolytic activity by qRT-PCR. We
depleted INTS13 and INTS11 in HL-60 cells andmeasured accu-
mulation of primary unprocessed U1 snRNA transcript. In the
absence of INTS13, the basal catalytic activity of the Integrator
complex was not affected (Figures 1C, S1A, and S1B). Addition-104 Molecular Cell 71, 103–116, July 5, 2018ally, we found that INTS13 is dispensable for proliferation of
HL-60 myeloid progenitor cells, whereas depletion of INTS11,
predictably, suppresses cell growth (Figure 1D). These data sug-
gest that INTS13 is not essential for the fitness of HL-60 cells and
may have a very limited function within the Integrator complex in
this cell model.
Next, we assessed whether the Integrator subunits were
required for gene activation associated to monocytic differentia-
tion of HL-60. HL-60 are progenitor-like cells of myeloid origin
(established from a patient with promyelocytic leukemia) (Gal-
lagher et al., 1979) that can be differentiated into functional
monocytes/macrophages upon stimulation with PMA (phorbol
myristate acetate), providing a convenient model of differentia-
tion. We examined the induction of the prototypical monocytic
gene CSF1R, which encodes the membrane receptor for the
monocytic cytokine macrophage colony-stimulating factor
(M-CSF) and is specifically induced during differentiation and
found that INTS11 is necessary for induction of CSF1R (Fig-
ure 1E), similar to its requirement for activation of immediate
early genes by the epidermal growth factor (Gardini et al.,
2014; Lai et al., 2015). Surprisingly, we also found INTS13 to
be required for induction of CSF1R (40%–70% reduction of
expression with small hairpin RNAs [shRNAs] for INTS13, Fig-
ures 1E and S1A for knockdown efficiency) suggesting that
this subunit, while dispensable in progenitor cells, may be neces-
sary for differentiation. We treated HL-60 cells with PMA for 48 hr
and measured expression of the surface marker CD11b by fluo-
rescence-activated cell sorting (FACS) analysis (Bender and
Beavo, 2006). Depletion of INTS13 with two different shRNAs re-
sulted in significant decrease of CD11b (Figures 1F and S1A). To
ensure that the effect of INTS13 on monocytic differentiation is
physiologically relevant and not dependent on HL-60 cells and
PMA stimulation, we purified CD34+ stem and progenitor cells
from cord blood. First, we assessed proliferation of primary cells
after depletion of INTS11 and INTS13 by measuring their meta-
bolic activity (MTT assay at day 4 post puromycin selection).
Similar to HL-60, only INTS11 depletion affected the growth of
primary progenitor cells (Figures 1G and S1B). Next, we lever-
aged INTS13-depleted CD34+ cells in a colony forming unit
(CFU) assay to assess their potential to form monocytic/macro-
phagic colonies in semi-solid medium upon stimulation with
M-CSF and granulocyte-macrophage (GM)-CSF for 2 weeks.
Our data indicated that INTS13 is required, in primary human
cells, to form monocytic colonies (Figures 1H, S1B, and S1C)
and suggest that INTS13 has a specific role in determining the
monocytic fate of progenitor cells.
The INTS13 Subunit of Integrator Is Required for
Activation of the Monocytic Transcriptome
We analyzed the transcriptome of HL-60 cells before and after
16 hr of PMA induction using RNA sequencing (RNA-seq).
PMA stimulation resulted in differential expression of 842 genes
(DESeq2, false discovery rate [FDR] <5%). Notably, the majority
(75%) of genes were upregulated (Figure 2A) and highly
enriched in gene ontology categories related to immune cell dif-
ferentiation and cellular movement, the latter being a feature of
differentiated macrophages (Figure S2A). In sum, a short treat-
ment of PMA triggered robust induction of genes that confer
Figure 1. Functional Dissection of the INTS11 and INTS13 Subunits of Integrator
(A) Immunoprecipitation of INTS13 in HL-60 cells. Immunoblots of antibodies against the Integrator subunits INTS1 and INTS11 show that the complex co-
precipitates with INTS13.
(B) Model representation of the Integrator protein complex, including the subunits INTS11 and INTS13.
(C) qRT-PCR of U1 snRNA in untreated HL-60 transduced with two different shRNAs against INTS11 and INTS13 shows that INTS11 depletion abrogates the
catalytic activity of the complexwhile it ismaintained upon INTS13 knockdown. Primers were designed downstream to the core snRNA sequence, after the region
recognized and cleaved by Integrator. shRNAs against luciferase (shLUC) were used as a control and ribosomal 18S as housekeeping gene. Data are
means ± SD.
(D) Five-day growth curve (MTT assay based) of unstimulated HL-60 cells transduced with shRNAs against INST11 and INTS13. Depletion of INTS13 does not
impair proliferation of HL-60, whereas depletion of INTS11 results in strong growth suppression. Two shRNAs per subunit were employed. Data are means ± SD.
(E) qRT-PCR of the monocytic gene CSF1R in PMA-treated HL-60 following depletion of either INTS11 or INTS13. Depletion of both INTS13 and INTS11
negatively affects CSF1R activation by PMA.
(F) HL-60 cells treatedwith PMAdifferentiate into amacrophagic-like stage and expression of the surface integrin CD11b is ameasure of differentiation. Themean
fluorescence intensity (MFI) of CD11b decreases in differentiated cells after depletion of INTS13 with two different shRNAs (48 hr post-PMA induction).
(G) Metabolic activity assay (MTT) was performed on CD34+ cells transduced with shRNAs for INTS11 and INTS13; data were collected at day 1 and day 4 after
selection with puromycin and plotted as fold change (FC; day 4 versus day 1). The MTT shows that also in primary cells the depletion of INTS13 does not impair
proliferation, whereas depletion of INTS11 results in strong growth suppression. Data are means ± SD.
(H) Colony-forming unit (CFU) assay of cord-blood-derived CD34+ cells infected with two different shRNAs for INTS13 and induced by M-CSF in methylcellulose
medium. The number of monocytic/macrophagic CFUs is significantly reduced in INTS13-depleted cells compared to control (shLUC). Data are means ± SD.
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Figure 2. Depletion of INTS13 Affects the Expression of Monocyte-Specific Genes
(A) 842 genes are DE between differentiated (PMA) and undifferentiated (CTRL) HL-60 cells (FDR <5%): 653 upregulated, 189 downregulated. The heatmap
displays the change in expression for the 653 upregulated genes.
(B) Heatmap and box plot show that the depletion of INTS13 in PMA treated HL-60 significantly decreases expression of genes associated to hematological
system and diseases.
(C) Ingenuity pathway analysis on 974 genes detected as DE in INTS13-depleted cells (FDR <5%) reveals enrichment for hematopoiesis related processes.
(D) Screenshots of the monocytic genes CSF1R and ITGAM, whose expression is strongly decreased upon INTS13 depletion in PMA-stimulated HL-60 cells.monocytic/macrophagic identity in HL-60 cells (similar to pri-
mary cells after a short treatment with M-CSF in liquid culture,
see Figures S2B and S2C). Next, we depleted INTS13 in HL-60
cells using lentiviral-transduced shRNAs. We found 974
genes differentially expressed (2 independent replicates, fold
change > ± 2, FDR <5%) with respect to control (shLUC). The
genes differentially expressed (DE) were enriched for hemato-
poiesis and immune cell development, as revealed by pathway
analysis (Figure 2C). Notably, we observed that monocytic/
macrophagic genes were not properly activated in the absence
of INTS13 (Figures 2B, S2D, and S2E). Among DE genes were
CSF1R (surface receptor for M-CSF) and ITGAM (part of the
monocytic adhesion molecule CD11b) (Figure 2D). Taken
together, our data suggest that INTS13 is critical for the timely
activation of monocytic genes and is essential to coordinate
transcriptome changes that define the monocytic/macrophagic
lineage.
Modular Properties of the Integrator Complex during
Differentiation of Myeloid Cells
To define the activity of the Integrator complex during lineage
commitment and differentiation of monocytes/macrophages,
we generated chromatin immunoprecipitation sequencing
(ChIP-seq) profiles before and after differentiation induced
by PMA (Figure 3A), to determine whether the dynamics of106 Molecular Cell 71, 103–116, July 5, 2018INTS11 and INTS13 binding at chromatin could explain their
different roles in progenitors andmonocytes. Our ChIP-seq anal-
ysis retrieved comparable numbers of binding sites for the two
subunits: 11,418 replicated peaks for INTS11-CTRL, 14,337
for INTS11-PMA, 14,408 for INTS13-CTRL, and 15,966 for
INTS13-PMA (Table S4).
To focus on the changes in Integrator binding upon differenti-
ation, we independently performed differential binding analysis
(CTRL versus PMA) using edgeR for each of the two subunits
(Robinson et al., 2010; FDR <10%, Table S1). With this analysis,
we detected 5,728 regions that significantly gained INTS13 bind-
ing upon differentiation (hereafter INTS13-gained regions; Fig-
ure 3B), and 2,438 regions with significant increase in INTS11
(hereafter INTS11-gained regions; Figure 3B). Notably, INTS11-
gained regions were largely enriched for proximal promoters
(62.2%), mirroring the known RNAPII-associated activity of the
complex, and displayed robust binding of INTS13 as well (Fig-
ures 3B and 3C). Conversely, INTS13-gained regions were
largely found distal from the TSS of protein-coding genes
(82.5%) and only partially overlapped with INTS11 (Figures 3B
and 3D).
We further investigated whether isolated INTS13-gained re-
gions could simply be the result of differences in pull-down effi-
ciency. First, we profiled INTS11 and INTS13 at all active U
snRNA genes (due to their high rate of transcription, U snRNA
loci bear the highest amount of the Integrator complex) and
found INTS11 to be more abundant than INTS13, suggesting
that the INTS11 antibody performs well in ChIP-seq (Figure 3E).
Next, we validated our findings by quantitative ChIP at select
loci. While INTS13 and INTS11 were recovered at similar levels
at the transcription start site of genes such as FOS and JUN (Fig-
ures 3F and S3), only INTS13 was significantly detected at inter-
genic loci for which ChIP-seq revealed isolated binding (Figures
3F and S3). INTS1 and INTS6, additional subunits of the full Inte-
grator complex, were also absent from INTS13-specific sites
(Figures 3F and S3). To investigate the modularity of the Inte-
grator complex in vivo, we subjected nuclear extract of HL-60
cells to fractionation on a size-exclusion column (Superose 6).
Notably, INTS13—along with other Integrator subunits (INTS1,
INTS6, INTS11)—elutes at a large molecular weight (>2 MDa),
comprising the full Integrator complex and associated RNAPII,
as previously described (Baillat et al., 2005). However, we
observed a second elution peak of INTS13, centered around
fraction 38 (200 kDa), which suggests the existence of
INTS13 as a sub-module (Figure 3G). To ensure that the smaller
INTS13 module is biochemically distinct from the previously
described INTS9/INTS11 heterodimer (Baillat et al., 2005;
Albrecht andWagner, 2012), we performed immunoprecipitation
of INTS13 from fraction 38 and subjected the eluate to LC-MS/
MS. Besides INTS13, we retrieved peptides of INTS14 and
INTS10 and no peptides of INTS11 (Figure S3). Together, our
data demonstrate that INTS13may also exist as a separatemod-
ule in the nucleoplasm, perhaps associated with additional Inte-
grator subunits andmay be selectively recruited to genomic sites
during monocytic differentiation, even in the absence of the full
Integrator complex.
INTS13 Binds to Monocytic Enhancers during
Differentiation
To understand the lineage-specific role of INTS13, we examined
the regions where it was recruited to chromatin upon differentia-
tion (5,728 INTS13-gained regions, Figure 3B). Topological anal-
ysis suggested that the large majority of INTS13-gained sites
(82.5% = 4,274 sites) were distal from the TSS of protein-coding
genes (Figure 3B). We identified the nearest genes for all the
distal regions, based on distance from TSS, and examined
gene ontology categories. We found that, collectively, INTS13-
gained distal regions were significantly associated with genes
implicated in immune cell development, trafficking, and hemato-
poiesis (Data S1). We hypothesized that these distal regions
could be enhancers, and we characterized them by performing
H3K27ac, H3K4me1, and total RNAPII ChIP-seq in HL-60 cells,
both untreated and upon 16 hr of PMA stimulation. We specif-
ically examined the status of acetylation and methylation at
INTS13-gained distal regions and found that 90% of these re-
gions overlap a peak of H3K4me1, but only50% also overlap a
peak of H3K27ac, supporting two distinct categories of INTS13-
bound enhancers (Figure 4A). The first category (representing
50% of all enhancers) comprised active enhancers with high
H3K27ac, RNAPII, and INTS11 (Figures 4A and 4B). In particular,
the intronic enhancer ofCSF1R, also known as the FIRE element
(Himes et al., 2001; Krysinska et al., 2007), was active and sig-
nificantly enriched for INTS13 (Figure 4B). Notably, these en-hancers boast transcription of eRNAs, underscoring their active
status (Figure S4). The second category of INTS13-bound en-
hancers was enriched in H3K4me1, but lacked RNAPII and
INTS11, and displayed low or undetectable H3K27ac (Figures
4A and 4B). These data suggested that INTS13 can also be re-
cruited to enhancers that are poised (Figure 4B). Therefore, we
speculated that INTS13 might be recruited to the active mono-
cytic enhancers at earlier time points of PMA induction, when
the enhancers are still in a poised/inactive state. Consistently,
time-course analysis of PMA induction suggested that binding
of INTS13 precedes activation of the enhancer as measured by
increase in acetylation of H3K27 (Figure 4C). In particular, the
enhancer of CSF1R displays an 25-fold increase of INTS13 at
4 hr post-induction, whereas the surge of H3K27ac (18-fold)
was detected at 6 hr. On the other hand, poised enhancers
bound by INTS13 at 16 hr of PMA treatment may be activated
at later time points, as suggested by our ChIP-seq analysis of
an extended time course of H3K27ac (Figure 4D).
In summary, we demonstrated that the INTS13 subunit of Inte-
grator selectively binds monocytic enhancers during lineage-
specific differentiation. INTS13 is recruited to enhancers before
acetylation of H3K27 and is likely to play a role in the enhancer
activation process.
INTS13 Targets EGR-Responsive Sites Genome-wide
The Integrator complex is believed to be recruited at chromatin
through its well-established interaction with the carboxy-termi-
nal domain (CTD) of RNAPII (Baillat et al., 2005; Egloff et al.,
2010). Our data suggested, for the first time, that a component
of Integrator is recruited at chromatin independently of the rest
of the complex and in the absence of RNAPII. Specifically, we
have established that INTS13 targets poised enhancer sites,
which are deprived of RNAPII and INTS11. We surmised that a
TF may be implicated in the recruitment of INTS13, whose pro-
tein sequence lacks any recognizable DNA/chromatin binding
domain. Therefore, we performed de novo motif analysis on
the 4,274 INTS13-gained enhancers enriched during differentia-
tion (see Figure 4A). We identified a matrix for the EGR1/EGR2
TFs as the most significant hit of the motif analysis (Figure 5A).
While other myeloid TF motifs were also retrieved (i.e. SPI1,
ERG/Ets, AP-1), their relative abundance and their significance
lag well behind that of EGR1/2 (see Data S2). Importantly, the
EGR1/2motif was centrally enriched, further underscoring its as-
sociation with INTS13. We tested the possibility that association
with INTS13 and EGR1 sites may be a conserved feature in
different model systems. We treated Jurkat lymphoblastic
T cells with PMA to mimic T cell activation and assessed the dis-
tribution of INTS13. Notably activation of Jurkat cells resulted in
de novo binding of INTS13 to 1,026 EGR1 sites, distinct from the
monocytic ones, which appeared to be enhancers associated
with T cell activity (Figures S5A–S5F; motif and ingenuity
pathway analysis (IPA) pathways analyses in Data S3).
The Early Growth Factor 1 and 2 are paralog genes that
encode zinc finger TFs widely implicated in cell growth and dif-
ferentiation. Importantly, EGR1 determines monocytic/macro-
phagic differentiation when expressed in primary and stable
cell lines, similar to EGR2 (Laslo et al., 2006; Nguyen et al.,
1993). We performed ChIP-seq for EGR1 in HL-60 cells andMolecular Cell 71, 103–116, July 5, 2018 107
Figure 3. Modular Properties of the Integrator Complex during Myeloid Differentiation
(A) Schematic panel describing the experimental pipeline. The catalytic activity of Integrator is impaired by INTS11 depletion, while it is not affected upon INTS13
depletion. The chromatin occupancy of the two subunits was profiled in undifferentiated (CTRL) and differentiated (PMA) cells by ChIP-seq with specific
polyclonal antibodies.
(B) Schematic panel describing the analytical pipeline. A differential binding analysis between CTRL and PMA conditions for INTS11 and INTS13 (edgeR,
FDR <10%) detected 2,438 INTS11-gained and 5,728 INTS13-gained regions, respectively. The majority of the INTS11-gained regions are proximal to protein
coding genes (distance <1 kb from nearest TSS), while the large majority of INTS13-gained regions are distal (distance >1 kb from TSS). INTS13 is bound to all of
the INTS11-gained regions. Conversely, a fraction of INTS13-gained regions is devoid of INTS11.
(C) An intronic region within the CD84 gene on Chr16 and the JUNB locus both display robust recruitment of INTS11 and INTS13 upon PMA induction.
(D) An intergenic region on Chr22 shows significant recruitment of INTS13, but not INTS11.
(E) Average profile of INTS11 and INTS13 at all active U snRNAs (Gencode annotation) displays stronger enrichment of INTS11 compared to INTS13, suggesting
that the INTS11 antibody performs well in ChIP-seq.
(F) ChIP-qPCR on the TSS of FOS shows comparable enrichment for multiple INTS subunits, while the qPCR performed on a distal INTS13-gained regions
suggests that INTS13 is the sole INTS subunit recruited. Data are means ± SD.
(legend continued on next page)
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Figure 4. INTS13 at Active and Poised Enhancers during Monocytic Differentiation
(A) 4,274 of the 5,728 INTS13-gained regions are distal elements. The heatmap shows (K-means clustering) that nearly half of these distal elements are active
enhancers (enriched for INTS13, INTS11, RNAPII, and the chromatin marks H3K27ac, H3K4me1), while the other half likely represent poised/inactive enhancers,
enriched for INTS13 and the chromatin mark H3K4me1.
(B) Average profiles of H3K27ac, H3K4me1 and INTS13 at active and poised enhancers, with representative examples.
(C) ChIP-qPCR of INTS13 and H3K27ac during a time course of early PMA induction (0, 2, 4, and 6 hr) for theCSF1R enhancer supports a model in which INTS13
binding precedes the activation of the enhancer. Data are means ± SD.
(D) Screenshots for two INTS13-gained enhancers classified as poised at 16 hr of PMA induction. These enhancers show increase of H3K27ac levels suggesting
their activation at a later time point following INTS13 binding.observed co-localization of EGR1 and INTS13 genome-wide
(Figures 5B and 5C). Motif analysis of EGR1 also retrieved an
EGR1/2 matrix nearly identical to that of INTS13 (Figure S5G).
ChIP-qPCR assay confirmed that EGR1 and EGR2 as both pre-
sent at select monocytic enhancers, suggesting their functional
redundancy in our system (Figure S5H). We reasoned that bind-
ing of EGR1/2 may be a prerequisite for INTS13 binding to
enhancers. To assess the importance of EGR1/2 in recruiting
Integrator, we performed ChIP-seq of INTS13 after depletion of
EGR1 in HL-60 (Figures 5D, 5E, and S5). INTS13 recruitment at(G) Nuclear extract of HL-60 cells was fractionated on a Superose 6 chromatogra
high-molecular-weight fractions, corresponding to the intact complex. Additional
catalytic subunit, INTS9. INTS13 is detected eluting with lower-molecular-weight
INTS13 can associate separately from the full complex in the nucleoplasm. Mol
fractions 20–46.enhancers was significantly impaired by EGR1 knockdown
(Wilcoxon’s rank-sum test, p < 2.2 3 1016, Figures 5D and
5E). While some INTS13 binding persisted, it must be noted
that EGR2 is still expressed in these cells, even if a much lower
level compared to EGR1, and that double depletion bears acute
effects on survival and cell cycle (Laslo et al., 2006). Furthermore,
we tested the overlap of INTS13 and EGR1 peaks pre- and post-
stimulation of PMA. In undifferentiated cells, EGR1 colocalized
with5% of INTS13 sites. Conversely, monocytic differentiation
boosted the share of overlapping peaks to 40% (Figure 5F).phy column in the presence of 0.5 M KCl. All Integrator subunits eluted with the
ly, INTS11 elutes in a known lower-molecular-weight interaction with the other
fractions that differ from INTS11 and other Integrator subunits, suggesting that
ecular weight standards are labeled above. Lanes are as follows: input, even
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Figure 5. INTS13 Targets EGR Responsive Sites Genome-wide
(A) De novo motif analysis of 4,274 INTS13-gained enhancers (summits ±100 bp). The EGR2/1 motif is the most significantly and centrally enriched. p value of
significance are plotted on the y axis, motif recurrence (total number of sites) is plotted on the x axis.
(B) EGR1 sites overlap INTS13 sites genome-wide, in differentiating HL-60 cells. The heatmap represents intensity of EGR1 and INTS13 ChIP-seq binding across
all EGR1 peaks (PMA-stimulated cells).
(C) Screenshot of the CSF1R intronic enhancer shows a significant recruitment of INTS13 and EGR1.
(D) Depletion of EGR1 significantly reduces the binding of INTS13 at all of the 4,274 INTS13-gained enhancers in PMA-stimulated HL-60 cells (Wilcoxon rank-sum
test p < 2.2 3 1016).
(E) Two intragenic enhancers of the CD84 locus are shown to exemplify loss of INTS13 upon EGR1 depletion.
(F) The overlap between INTS13 and EGR1 peaks significantly increases (5%–40%) upon PMA induction in HL-60 cells (Wilcoxon rank-sum test p < 2.23 1016).Collectively, we demonstrated that EGR1 is a determinant of
INTS13 binding at enhancers during monocytic differentiation,
while progenitor cells maintain distinct binding profiles for
both. These data suggest that additional factors may be required
to draw INTS13 to EGR1-responsive elements.
NAB2 Is an Essential Co-factor for Enhancer Activation
Mediated by INTS13 and EGR1/2
We surmised that INTS13 binding to EGR1/2 at enhancers may
be overall mediated by protein-protein interactions; therefore,
we performed proteomic analysis of untreated and differenti-
ating HL-60 cells in two independent replicates. We used rabbit
antibodies to immunoprecipitate endogenous INTS13 and sub-
jected the eluate to liquid chromatography-tandem mass
spectrometry (LC-MS/MS) analysis. As expected, INTS13 co-
precipitated the full Integrator complex and subunits of
RNAPII (Figure 6A; Table S2). Next, we looked for non-Inte-
grator components in our proteomic analysis. We previously
described that widespread recruitment of INTS13 to EGR1/2
monocytic enhancers (Figures 3 and 5) is specific to differenti-110 Molecular Cell 71, 103–116, July 5, 2018ating monocytes. In fact, INTS13 is largely dispensable for un-
differentiated progenitor cells but is required for maturation into
functional monocytes/macrophages (Figures 2 and S2). We
reasoned that additional protein partners of INTS13 may be
specific to differentiating cells; therefore, we calculated the
ratio of peptides retrieved in differentiating (PMA) over undiffer-
entiated (CTRL) HL-60 cells. Notably, we identified the NGFI-A-
binding protein 2 (NAB2) as the most significantly enriched
protein. NGFI-A is an alias for EGR1, since NAB2 and its func-
tional homolog, NAB1, were originally identified as partners of
EGR1 and EGR2 (Russo et al., 1995, Svaren et al., 1996). We
confirmed the association of NAB2 with INTS13 by co-immuno-
precipitation experiments from the nuclear extract of HL-60
cells and observed that NAB2 was lowly abundant in untreated
cells but accumulated upon differentiation (Figure 6B). Impor-
tantly, we observed a similar regulation in primary cells:
NAB2 was barely detectable in primary human stem and pro-
genitor cells (CD34+) and increased dramatically during mono-
cytic differentiation stimulated by M-CSF (Figure S6). To further
validate the interaction of NAB2 with INTS13/Integrator, we
generated stable cell clones expressing FLAG-tagged NAB2
and performed a reverse LC-MS/MS experiment. FLAG affinity
purification of NAB2 complexes co-purified the EGR proteins
and INTS13, along with several other subunits of Integrator
(Figure 6C). Our data imply that NAB2 bridges the interaction
of INTS13 with EGR1/EGR2 and suggest that a ternary com-
plex composed of INTS13/NAB2/EGR may form at monocytic
enhancers. We performed ChIP-seq of endogenous NAB2 in
HL-60 cells and found a distinct distribution of NAB2 peaks
during differentiation. Consistent with INTS13, NAB2 showed
a significant recruitment at the 4,274 monocytic enhancers
(Figure 6D), colocalizing with EGR1 and INTS13 at most of
these sites (Figures 6D, 6E, and S6). Interestingly, best correla-
tion between INTS13 and EGR1 happens on NAB2 peaks (Fig-
ure S6C). Notably, NAB2 binding dynamics resembled those of
INTS13, preceding acetylation of the enhancer, such as in
CSF1R (Figure S6). Further, ChIP-seq on PMA-induced HL-60
showed that INTS13 binding at the 4,274 monocytic enhancers
was severely impaired by NAB2 depletion (two independent
shRNAs; p < 0.0001; Figures 6F, 6G, and S6). This suggested
NAB2 as the molecular bridge that recruits INTS13 to
EGR1/2-responsive elements. Moreover, 679 genes were DE
in PMA-treated HL-60 upon NAB2-KD (517 downregulated,
FDR <5%, Figures 6H and 6I). IPA analysis confirmed enrich-
ment in hematopoiesis pathways (Figures 6H, 6I, and S6),
thus recapitulating the results obtained upon depletion of
INTS13 (Figures 2B–2D).
If NAB2 is an essential co-factor that elicits enhancer activa-
tion via recruitment of INTS13, depletion of NAB2 should also
impair development of monocytic/macrophagic cells and phe-
nocopy the effect of either INTS13 depletion (Figures 1F and
1H) or EGR1 depletion (Laslo et al., 2006). Coherently, both
NAB2 and EGR1 were indeed required for differentiation of
HL-60 cells (mean fluorescence intensity [MFI] of CD11b, Fig-
ure 6J) and were essential to form M-CSF-derived monocytic
colonies from CD34+ stem and progenitor cells (Figures 6K
and S6).
To further validate the INTS13/NAB2 functional association in
physiological conditions, we performed additional ChIP-seq ex-
periments using circulating monocytes obtained from the
peripheral blood of healthy donors. Terminal differentiation
of monocytes into adherent macrophages reignites the
enhancer-promoter network that is responsible for the earlier
differentiation stages (CD34+ to monocytes) and provides a
physiological model for enhancer regulation (Heinz et al.,
2010; Pham et al., 2012). Consistent with our findings from
HL-60, the ChIP-seq data from the differentiating macrophages
supported a significant recruitment of both INTS13 and NAB2
at the previously identified 4,274 monocytic enhancers,
including CSF1R (Figure S7). Furthermore, we independently
depleted EGR1 and NAB2 from a pool of mobilized CD34+
cells, performed INTS13 ChIP-seq at day 5 of monocytic differ-
entiation, and observed, in both cases, a sharp and significant
decrease of INTS13 across all the genome (Figure S7).
Together, the data obtained in primary cells fully support our
previous findings in HL-60 cells, and in particular the role of
NAB2 and EGR1 in the recruitment of INTS13 at thousands
of lineage-specific enhancers.The INTS13/EGR/NAB2 Axis Brings about Activation of
Poised Enhancers
We performed chromosome conformation capture (3C) on the
enhancer of CSF1R to infer the consequences of INTS13 deple-
tion on genome architecture. During differentiation of HL-60
cells, we detected a robust interaction between the intronic
enhancer of CSF1R and the proximal promoter, as compared
to other regions within the CSF1R gene or with the promoter of
neighboring genes (Figure 7A). Specifically, we observed an
5-fold decrease in the frequency of enhancer-promoter inter-
actions following depletion of INTS13, while all non-specific con-
tact pairs used as controls (NEG1 to NEG5) were not affected
(Figure 7A). This assay demonstrated the functional requirement
of INTS13 for enhancer-promoter looping of a monocytic
enhancer engaged during differentiation.
Collectively, our data demonstrated that INTS13/Integrator
targets poised enhancers that are required for monocytic differ-
entiation. While these enhancers are primarily bound by the
EGR1/2 TFs, the co-factor NAB2 is the essential molecular
bridge that allows binding of INTS13 to EGR-dependent en-
hancers. Altogether, the INTS13/EGR1/NAB2 axis is functionally
required to coordinate and elicit activation of monocytic and
macrophagic genes during myeloid differentiation (Figure 7B).
DISCUSSION
In this work, we characterize a novel function of the Integrator
protein complex and demonstrate that an accessory (non-cata-
lytic) subunit of a general activator machinery can operate as a
mediator of lineage-determining TFs. We characterize a novel
mechanism of enhancer regulation, in which a co-activator sub-
unit (INTS13), a DNA-binding TF (EGR1/2), and a non-DNA-bind-
ing co-factor (NAB2) take part. We demonstrate co-occupancy
of this ternary complex at chromatin and capture their physical
interaction by co-immunoprecipitation and LC-MS/MS. Our
data suggest that the INTS13/EGR/NAB2 axis is a priming com-
plex for enhancers. In fact, we initially found that INTS13/EGR/
NAB2 bind to active and poised enhancers. Poised enhancers,
which lack H3K27 acetylation but retain mono-methylation of
H3K4, have been previously described in differentiated and mul-
tipotent cells (Creyghton et al., 2010; Ostuni et al., 2013; Rada-
Iglesias et al., 2011; Zentner et al., 2011). We showed that
INTS13 and NAB2 target poised enhancers during monocytic
differentiation, preceding the wave of H3K27 hyperacetylation.
Persistently poised enhancers, which we detect after 16 hr of
PMA stimulation, may become activated at a later time point,
as our data suggest. It is also possible that additional co-factors
are needed to elicit activation of a subset of INTS13/EGR1/NAB2
targets. Importantly, enhancers regulated by INTS13, EGR1, and
NAB2 are required for proper expression of genes that confer
monocytic identity. Our analysis of EGR1 represents the first
profiling of this zinc finger TF in differentiating progenitors and re-
veals the unexpected breadth of its role as a lineage-determining
factor via enhancer regulation. TFs such as PU.1 and ERG (Ets)
are generally considered master regulators of myeloid commit-
ment (Álvarez-Errico et al., 2015). In fact, when we searched
for DNA motifs associated with INTS13-enhancers, we retrieved
both PU.1 and ERG, though less significantly enriched thanMolecular Cell 71, 103–116, July 5, 2018 111
Figure 6. NAB2 Is an Essential Co-factor of Monocytic Differentiation and Mediates INTS13 Binding at EGR1 Sites
(A) Endogenous INTS13 was affinity-purified from undifferentiated and differentiating HL-60 cells. The interactome of INTS13 was detected by LC-MS/MS. The
plot shows adjusted protein enrichment values (iBAQ, y axis) and the ratio of peptides in differentiated (PMA) versus undifferentiated (CTRL) cells. INTS13 in-
teracts with nearly all Integrator subunits and RNAPII, interaction with the EGR1 co-factor NAB2 is specific to monocytic differentiation.
(B) Immunoprecipitation of INTS13 in undifferentiated (CTRL) and differentiated (PMA) HL-60 cells confirms the interaction between INTS13 and NAB2 after PMA
treatment.
(C) LC-MS/MS analysis of stable HL-60 clones expressing exogenous FLAG-NAB2. NAB2 was affinity purified by anti-FLAG conjugated beads. NAB2 interacts
with NAB1, EGR-family members (EGR1, EGR2, EGR3), INTS13, and other Integrator subunits.
(D) Heatmaps of NAB2, INTS13, and EGR1 ChIP-seq in undifferentiated (CTRL) and/or differentiated (PMA) HL-60. Upon PMA treatment, NAB2, INTS13, and
EGR1 co-localize at INTS13-gained enhancers.
(E) Screenshot of the intragenic CSF1R enhancer shows recruitment of NAB2 and INTS13 during differentiation.
(F) Screenshot of the CSF1R intragenic enhancer shows reduction of INTS13 recruitment upon NAB2 depletion.
(G) Average profiles and box-plot display a significant decrease of INTS13 at the 4,274 INTS13-gained enhancers upon NAB2-KD (two different shRNAs).
(H) RNA-seq analysis identified 517 genes downregulated upon NAB2-KD (two different shRNAs) during PMA-induced differentiation. IPA analysis for these
genes revealed enrichment for pathways associated to hematopoiesis and differentiation, recapitulating the results previously obtained with INTS13 depletion
(Figure 2).
(legend continued on next page)
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Figure 7. Targeted Enhancer Activation by
INTS13
(A) Chromosome conformation capture (3C) re-
veals that depletion of INTS13 elicits a significant
reduction of the interaction frequency between the
intragenic enhancer of CSF1R (FIRE element) and
the promoter of the same gene, suggesting that
INTS13 mediates loop formation, enhancer/pro-
moter interaction, and ultimately the expression of
the CSF1R (see also Figure 2D). As control, we
gauged the interaction frequency between the
enhancer (anchor) and 5 additional surrounding
sites (NEG1 to NEG5), including the TSS of 3
additional genes, the 30 end of one gene and a
non-enhancer intronic region of CSF1R. Data are
means ± SD.
(B) We propose amodel for the role of Integrator in
targeted enhancer activation during cell differen-
tiation. In undifferentiated cells, lineage-specific
genes are not expressed, and their corresponding
enhancers are inactive or poised (I). Upon lineage
commitment, EGR1 recognizes and binds to its
motifs across monocytic enhancers, together with
NAB2 (II). INTS13 is recruited by the NAB2/EGR1
complex, and co-localizes at the same enhancers
(III). Following INTS13 priming of the enhancers,
the Integrator complex is assembled, facilitating
enhancer activation and chromatin looping to
ultimately activate transcription of the target
genes (IV).EGR1 and not centrally positioned with respect to the INTS13
peak summit, underscoring that the Integrator complex prefer-
entially operates via EGR1 during monocytic differentiation.
EGR1 and EGR2 were previously proposed to regulate
monocytic differentiation by repressing granulocytic genes(I) Prototypical monocytic genes such as CSF1R and CD84 are severely downregulated by NAB2 depletion
(J) Mean fluorescence intensity of CD11b is impaired in differentiated HL-60 cells after depletion of NAB2 with
(K) Colony-forming unit (CFU) assay of cord-blood-derived CD34+ cells infected with shRNAs against NAB2
macrophagic colonies is significantly reduced in both NAB2- and EGR1-depleted cells when compared to c
M
(Krishnaraju et al., 2001; Laslo et al.,
2006; Nguyen et al., 1993). Instead, our
data suggest that EGR1 and EGR2 (which
we find functionally redundant by ChIP
and proteomic analyses) directly regulate
enhancer-mediated activation of mono-
cytic- and macrophagic-specific genes,
such as CSF1R. Furthermore, we re-
vealed an essential and unexpected role
of the co-factor NAB2. EGR1 and EGR2
were previously shown to interact with
NAB2 by two-hybrid and in vitro pull-
down experiments; such interaction is
deemed important for neuronal differenti-
ation and development (Kumbrink et al.,
2005, 2010; Svaren et al., 1996). Previous
biochemical evidences suggested that
NAB2 merely served as co-repressor fora subset of EGR1 target promoters (Lucerna et al., 2003; Svaren
et al., 1996). Our data reveal, instead, that NAB2 functions as a
molecular switch, determining INTS13 recruitment at EGR1 sites
in both primary and HL-60 cells. Furthermore, depletion of NAB2
phenocopies loss of INTS13 and EGR1: cell lines and primaryin RNA-seq experiments.
two different shRNAs (16 hr post-PMA induction).
and EGR1 shows that the number of monocytic/
ontrol. Data are means ± SD.
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CD34+ cells depleted of NAB2 fail to activate a monocytic tran-
scriptome and are blocked at a progenitor stage. Collectively,
we present the first comprehensive molecular characterization
of NAB2 and provide the first evidence of NAB2 binding profile
at chromatin. We propose that the role of NAB2 in myeloid
differentiation is to regulate timely activation of monocytic en-
hancers by recruiting INTS13. Beyond monocytic differentiation,
EGR1/NAB2-dependent enhancers may play a role in other
developmental pathways. For instance, we suggest that T cell
activation may also require INTS13 as a modulator of EGR1
sites. Also, EGR1 and NAB2 were previously implicated in
neural development, raising the possibility that INTS13 is a
major effector of cell commitment and differentiation in such
context.
Another critical finding of our work is that the Integrator com-
plex is not functionally homogeneous. In particular, we focus on
the INTS13 subunit, which was recently described as an integral
component of the human and Drosophila Integrator complexes
(Chen et al., 2012; Malovannaya et al., 2011). Our data show
that INTS13 is, de facto, a physical and functional submodule
of Integrator. INTS13 is part of the full Integrator complex in
myeloid cells (Figures 1A, 3G, and 6A) but can also exist as a
small subcomplex (perhaps associated with additional INTS
subunits, Figure 3G). INTS13 is not required for the core catalytic
activity of Integrator (RNA endonucleolysis), nor is it essential for
cell growth of progenitor and stem cells under resting conditions
(Figure 1) but is indispensable for cell commitment and differen-
tiation. Unlike INTS11, INTS9, and INTS1 (Baillat et al., 2005;
Chen et al., 2012), INTS13 is dispensable for processing of U
snRNAs and, likely, for termination of noncoding eRNAs that em-
ploys the same catalytic activity centered around the b-CASP
domain of INTS11 (Lai et al., 2015). A previous report suggested
that INTS13 (also known as ASUN) had an influence on U snRNA
processing (Chen et al., 2012). However, the effect of INTS13
depletion on a GFP-UsnRNA reporter system was significantly
lower than the effect of INTS9 depletion (Chen et al., 2012).
Furthermore, reporter constructsmay not entirely reflect Integra-
tor’s activity at endogenous U snRNA loci. However, we cannot
exclude that INTS13 may retain regulatory activity toward U
snRNA processing in lower eukaryotes. Further studies are
needed to address the evolution of the Integrator complex and
to determine the complete map of core and accessory subunits
of this essential transcriptional regulator.
In conclusion, our data suggest that large and ubiquitously ex-
pressed co-activator complexes are not just passive facilitators
of transcription but may actively partake in the organization of
cell- and tissue-specific enhancer-promoter activity.STAR+METHODS
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Mouse monoclonal anti-EGR1 Santa Cruz Biotechnology Cat#sc-515830
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Superose 6 10/30 GL column GE Life Science Cat# 17517201CONTACT FOR REAGENT AND RESOURCE SHARING
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dro Gardini (agardini@wistar.org)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
293T were obtained from American Type Culture Collection (ATCC) andmaintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% super calf serum (GEMcell) and 2 mM L-glutamine (Corning). HL-60 cells were obtained from ATCC and
maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Corning) supplemented with 10% (v/v) of super calf serum
(GEMcell) or Tet system approved fetal bovine serum (Clontech) and 2 mM of L-glutamine (Corning). Jurkat cells were a kind gift
of Dr. M. Abdel-Mohsen (Wistar Institute).
Primary cells
Bone marrow (BM)-derived CD34+ were obtained from Calabretta’s lab at Thomas Jefferson University. CD34+ CD33- cells were
sorted at the Flow Cytometry facility at Wistar Institute. Fetal liver (FL)-derived CD34+ cells were obtained from Stem Cell and Xeno-
graft Core at University of Pennsylvania and weremaintained in StemSpan SFEMmedium supplemented with CC100 cytokine cock-
tail (Stem Cell Technologies). De-identified human cord blood (CB) was obtained from volunteers with informed consent at Helen F.
Graham Cancer Center and Research Institute at Christiana Hospital. Mononucleated cells (MNC) were separated with Ficoll-
Hystopaque Plus (GE Healthcare). CD34+ cells were then isolated using human CD34 MicroBeads Kit (Miltenyi Biotec) following
manufacturer’s instructions. CD34+ were maintained in StemSpan SFEM medium supplemented with 1X CC100 cytokine cocktail.
BM- and FL-derived CD34+were used for CFU assay, BM-, FL- andCB-derived CD34+were in vitro differentiated and used for RNA-




HL-60 cells were lentivirally transduced through one round of spinoculation (1800 RPM, 45 minutes at 30C, brake off) and selected
with 2 mg/ml puromycin (InvivoGen). CD34+ cells were spinoculated with ultracentrifuge-concentrated lentivirus at 1800 RPM, for
45 minutes at 30C, incubated overnight at 37C in the virus-containing medium, followed by another round of infection the following
day. Cells were collected, washed and selected with 1 mg/ml puromycin in StemSpan SFEM medium supplemented with CC100
cytokine cocktail (Stem Cells Technologies).
In vitro differentiation
HL-60 cells were differentiated with 100 nM Phorbol 12-myristate 13-acetate (PMA) in growing medium and the status of differenti-
ation was assessed by flow cytometry. Briefly, cells were incubated in 1X PBS supplemented with 1% heat-inactivated FBS and
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with the suitable fluorochrome-conjugated antibody for 30 minutes at 4C. Cells were then washed with 1X PBS, fixed in 1%
formaldehyde (Sigma-Aldrich) in 1X PBS. Cells were then washed twice with cold PBS and data acquired with a BD LSR II flow
cytometer (BD Bioscience). Analyses were performed and elaborated using FlowJo Software v10.0.7 (FlowJo, LLC).
CD34+ cells were differentiated in monocytes in SFEM supplemented with 100 ng/ml SCF, 10 ng/ml IL-3, 50 ng/ml M-SCF and
25 ng/ml GM-CSF (Peprotech). Expression of CD14 was assessed by flow cytometry at different days of treatment as a measure
of differentiation (CD14+ cells: day 0: 0%–4%, day 3: 3%–7%, day 7: 20%–40%). Circulating monocytes were differentiated into
adherent macrophages in IMDM supplemented with 10% heat-inactivated FBS and 25 ng/ml of human recombinant GM-CSF
(Peprotech).
Knockdown of INTS11, INTS13, EGR1 and NAB2
pLKO.1, tet-pLKO-puro and pLENTI-CMV-GFP-Puro vectors were obtained from Addgene (#10879, #21915 and #17448). pLKO.1-
shINTS11 #1 (TRCN0000161507), pLKO.1-shINTS11 #2 (TRCN0000161070), pLKO.1-shNAB2 #1 (TRCN0000019544) and pLKO.1-
shNAB2 #3 (TRCN0000019546) were obtained from the Molecular Screening Facility at the Wistar Institute. A shRNA against
luciferase was used as control.
shINTS13#1, shINTS13#2, shEGR1, shNAB2 #2 were designed with the Broad Institute algorithm (https://portals.broadinstitute.
org/gpp/public/) and subsequently cloned in either pLKO.1 or tet-pLKO vectors. Sequences of the designed shRNAs are listed in
Table S3. Expression of tet-pLKO-shEGR1 was induced with 2 mg/ml doxycycline (Sigma-Aldrich) for 72 hours in growing medium.
NAB2 overexpression
To generate the pLENTI-FLAG-NAB2 vector, NAB2 full-length cDNA was amplified by PCR using the Phusion high-fidelity DNA po-
lymerase kit (New England Biolabs), cloned into the pFLAG-puro vector and sub-cloned into the pLENTI-CMV-GFP-Puro using
Gibson Assembly Master Mix (New England Biolabs). Primer sequences are listed in Table S3.
Western blot
Cells were harvested and washed three times in 1X PBS and lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Igepal,
0.5% sodium deoxycholate, 0.1% SDS, 500 mM DTT) supplemented with 1 mg/ml aprotinin, 1 mg/ml leupeptin (Sigma) and 1 mg/ml
pepstatin (BMB). 50 mg of whole cell lysate were loaded in Bolt 4%–12%Bis-Tris Plus gel (Invitrogen) or NovexWedgeWell 10% Tris-
Glycine Gel (Invitrogen) and separated through gel electrophoresis (SDS-PAGE) in Bolt MES running buffer (Invitrogen) or Tris-
Glycine-SDS buffer (Bio-Rad), respectively. Separated proteins were transferred to ImmunBlot PVDF membranes (BioRad) for
antibody probing. Membranes were incubated with 10% BSA in TBST for 30 minutes at room temperature, then incubated for 2h
at RT or overnight at 4Cwith the suitable antibodies diluted in 5%BSA in 1X TBST, washed with TBST, and incubated with a dilution
of 1:10000 of HRP-linked anti-mouse or anti-rabbit secondary antibody (Cell Signaling) for one hour at RT. Antibodies were then visu-
alized using Clarity Western ECL substrate (Biorad) and imaged with Fujifilm LAS-3000 Imager (Fujifilm).
Real-time quantitative polymerase chain reaction
Cells were lysed in Tri-reagent and RNA was extracted using the Direct-zol RNAMiniPrep kit (Zymo research). 1 mg of template RNA
was retrotranscribed into cDNA using randomprimers and the Revertaid first strand cDNA synthesis kit (Thermo Scientific) according
to manufacturer directions. 50 ng of the cDNA were used for each real-time quantitative PCR reaction with 0.4 mM of each primer,
10 mL of iQ SYBR Green Supermix (BioRAD) in a final volume of 20 ml, using a CFX96 real-time system (BioRAD). Thermal cycling
parameters were: 3 minutes at 95C, followed by 40 cycles of 10 s at 95C, 20 s at 63C followed by 30 s at 72C. Each sample
was run in triplicate. 18S rRNA weas used as normalizer. Primer sequences are reported in Table S3.
Colony-forming unit (CFU) assays
Infected FL- or BM- derived CD34+ cells were cultured at 37C at the density of 1.23 103/ml in SF H4236 methylcellulose (Stem Cell
Biotechnologies) containing medium supplemented with 15% heat-inactivated fetal bovine serum (Sigma-Aldrich) or 15% of super
calf serum (GEMcell), 100 ng/ml SCF, 20 ng/ml IL-3, 50 ng/ml FLT3L, 20 ng/ml IL-6, 50 ng/ml M-CSF, 30 ng/ml GM-CSF. Colonies
were counted after 10-14 days. Colonies were stained overnight in a solution of 5 mg/ml of Nitrotetrazolium Blue chloride (Sigma-
Aldrich) in water.
Proliferation assay
HL-60 or CD34+ cells were seeded at 20,000 cells/ml in 96-well plates at day 1. Cell proliferation was determined every 24h (HL-60) or
4 days later (CD34+ cells) using the cell growth determination kit MTT based (Sigma-Aldrich), following manufacturer’s instruction.
Immunoprecipitation
HL-60 cells were washed twice with ice cold PBS before resuspension in BC100 (20mM Tris pH 8.0, 0.1M KCl, 0.1% NP-40, 10%
glycerol, 0.2mMEDTA, 0.5mMDTT, 1 mg/ml each of protease inhibitors aprotinin, leupeptin, and pepstatin), and incubated at 4C fore4 Molecular Cell 71, 103–116.e1–e7, July 5, 2018
five minutes. The pellet was resuspended in buffer C (20mM Tris pH 8.0, 1.5mM MgCl2, 0.42M NaCl, 25% glycerol, 0.2mM EDTA,
0.5mMDTT, protease inhibitors) and incubated at 4C for 30minutes. For chromatin-enriched nuclear extracts, Benzonase nuclease
(Sigma-Aldrich) was added after 15 minutes and incubated for an additional 30 minutes at 4C. The resulting extract was spun down
at 12,000rpm for 30 minutes. The pellet was discarded and supernatant kept as nuclear extract. The nuclear extract was dialyzed
overnight in BC80 (20mM Tris pH 8.0, 80mM KCl, 0.2mM EDTA, 10% glycerol, 1mM b-mercaptoethanol, 0.2mM phenylmethylsul-
fonyl fluoride (PMSF)), cleared and stored at 80C.
500 mg (for western blot) or 2-4mg (for mass spectrometry) of nuclear extract was diluted in co-IP buffer (20mMTris pH 7.9, 100mM
NaCl, 0.1%NP-40, protease inhibitors). INTS13 antibody-crosslinked Dynabeads Protein A (Invitrogen), or ANTI-FLAGM2 affinity gel
(Sigma-Aldrich) were incubated with nuclear extract at 4C for four or two hours, respectively. Supernatant kept as flow-through.
Beads were washed three times with co-IP buffer, followed by one wash with 0.05% NP-40 in PBS. Glycine elution was performed
with agitation in 0.1M glycine pH 3.0 for one minute, and 1M Tris base pH 11.0 was added to neutralize the pH of the eluate. Flag-
peptide competition elution was performed by incubation with excess FLAG peptide (Sigma-Aldrich) at 4C for 30 minutes. Eluate
was stored at 80C or prepared for SDS-PAGE.
Size-exclusion chromatography
0.4 mL of HL-60 nuclear extract (5mg total protein) was loaded onto a Superose 6 10/30 GL column (GE Life Science) equilibrated
with BC500 buffer. Flow rate was fixed at 0.4 ml/min, and 0.4 mL fractions were collected.
Antibody crosslinking
Dynabeads Protein A (Invitrogen), 500 ml, were washed three timeswith PBS prior to crosslinking with 20 mg INTS13 antibody (Bethyl).
Beads and antibody were diluted in PBST and incubated with agitation for 2 hours at room temperature. The antibody-bound beads
were washed three times with 200mM triethanolamine pH 8.2, then resuspended in freshly made 10mM DMP (dimethyl pimedlimi-
date dihydrochloride) in 200mM triethanolamine pH 8.2 and gently rotated for 30 minutes at room temperature. The crosslinking re-
action was stopped with gentle rotation in 50mM Tris pH 7.5 for 15 minutes. Crosslinked beads were washed three times with PBST,
twice with 0.1M glycine pH 3.0, twice with PBST, and stored in PBST + 0.02% sodium azide at 4C.
Mass spectrometry
After co-immunoprecipitation, eluates were prepared for SDS-PAGE as described previously. The eluates were run into a 10% Tris-
glycine gel at 110V for ten minutes. The gel was stained with Colloidal Blue staining kit (Invitrogen), and further processed at the pro-
teomics facility at theWistar Institute. Briefly, the gel lanes were excised, digested with trypsin, and analyzed by LC-MS/MS on the Q
Exactive HF mass spectrometer. The data were searched against the UniProt human database (September 2016) and provided se-
quences using MaxQuant 1.5.2.8 (Cox andMann, 2008). False discovery rates for protein and peptide identifications were set at 1%.
Chromosome conformation capture (3C)
ChromosomeConformation Capturewas performed as reported in (Dekker et al., 2002) withminor changes. 13 107 HL-60 cells were
fixed in 1% formaldehyde for 10 min at room temperature for cross-linking. The reaction was quenched with 0.25 M glycine and cells
were collected by centrifugation at 225 g for 8 minutes at 4C. Cell pellet was lysed in 5 mL cold lysis buffer (10 mM Tris-HCl, pH 7.5;
10 mM NaCl; 5 mM MgCl2; 0.1 mM EGTA) with freshly added protease inhibitors on ice for 10 minutes.
Isolated nuclei were collected by centrifugation at 400 g for 5 min at 4C then re-suspended in 0.5 mL of 1X Cutsmart buffer (New
England Biolabs) with 0.3% SDS and incubated for 1 h at 37C while shaking at 900 rpm. Next, samples were incubated for 1 hr at
37C after addition of 2% Triton X-100.
400Uof PstI restriction enzyme (NewEngland Biolabs) were added to the nuclei and incubated at 37Cover night while shacking at
900 rpm. 5 mL of samples were collected before and after the enzyme reaction to evaluate digestion efficiency.
The reaction was stopped by addition of 1.6% SDS and incubation at 65C for 30 minutes while shaking at 900 rpm. The sample
was then diluted 10-fold with 1.153 ligation Buffer (660 mM Tris-HCl, pH 7.5, 50 mMDTT, 50 mMMgCl2, 10mMATP) and 1% Triton
X-100 and incubated for 1 h at 37C while shaking at 900 rpm. 100 U of T4 DNA ligase (NEB) were added to the sample and the re-
action was carried at 16C over night. For each sample, 300 mg of Proteinase K were added for protein digestion and de-crosslinking
at 65C overnight. On the next day, RNA was removed by adding 300 mg of RNase and incubating the sample for 1 h at 37C. DNA
was purified twice by phenol-chloroform extraction, and precipitated with ethanol over night at 80C. Purified DNA was quantified
by qubit, diluted to 3ng/ul and analyzed by real time quantitative PCR. TheDCtmethodwas applied for analyzing data, using the actin
Ct values as control.
Primer sequences are reported in Table S3.
ChIP-seq and ChIP-qPCR sample processing
Samples from different conditions were processed together to prevent batch effects. ChIP-seq was performed as previously
described (Lai et al., 2015), with some modifications. For each replicate, 10 million HL-60 cells were cross-linked with 1%Molecular Cell 71, 103–116.e1–e7, July 5, 2018 e5
formaldehyde for 5 min at room temperature, harvested and washed twice with 1 3 PBS. The pellet was resuspended in ChIP lysis
buffer (150 mM NaCl, 1% Triton X-100, 0,7% SDS, 500 mM DTT, 10 mM Tris-HCl, 5 mM EDTA) and chromatin was sheared to an
average length of 200–400 bp, using a Covaris S220 Ultrasonicator. The chromatin lysate was diluted with SDS-free ChIP lysis buffer.
For ChIP-seq, 10 mg of antibody (5 mg for histone modifications) was added to the 10 million lysated cells along with Protein A
magnetic beads (Invitrogen) and incubated at 4C overnight. For RNAPII ChIP-seq, a custom rabbit polyclonal antibody raised
against the N-terminal domain was used. On day 2, beads were washed twice with each of the following buffers: MixedMicelle Buffer
(150mMNaCl, 1%Triton X-100, 0.2%SDS, 20mMTris-HCl, 5 mMEDTA, 65% sucrose), Buffer 500 (500mMNaCl, 1% Triton X-100,
0.1% Na deoxycholate, 25 mM HEPES, 10 mM Tris-HCl, 1 mM EDTA), LiCl/detergent wash (250 mM LiCl, 0.5% Na deoxycholate,
0.5% NP-40, 10 mM Tris-HCl, 1 mM EDTA) and a final wash was performed with 13 TE. Finally, beads were resuspended in 13 TE
containing 1%SDS and incubated at 65C for 10 min to elute immunocomplexes. Elution was repeated twice, and the samples were
further incubated overnight at 65C to reverse cross-linking, along with the untreated input (5% of the starting material). On day 3,
after treatment with 0.5 mg/ml proteinase K for 3 h, DNA was purified with Zymo ChIP DNA Clear Concentrator kit (Zymo research)
and quantified with QUBIT. Barcoded libraries were made with NEB ULTRA II DNA Library Prep Kit for Illumina, and sequenced
on Illumina NextSeq 500, producing 75bp SE reads. For ChIP-qPCR samples, on day 3 DNA was purified with Wizard SV Gel
and PCR Clean-Up system (Promega), resuspended in 200 ul and 5 ul were for each PCR reaction. Primer sequences are listed
in Table S2
ChIP-seq analyses
Sequences were aligned to the reference hg19, using Burrows Wheeler Alignment tool (BWA), with the MEM algorithm (Li, 2013).
Aligned readswere filtered based onmapping quality (MAPQ> 10) to restrict our analysis to higher quality and likely uniquelymapped
reads, and PCR duplicates were removed. We called peaks for each individual using MACS2, at 5% FDR, with default parameters
(Zhang et al., 2008). Heatmaps and average profiles were generated with ChAsE v. 1.0.11 (Younesy et al., 2016). EdgeR (Robinson
et al., 2010) was used to detect cis-regulatory elements (CREs) which significantly gained INTS13 and/or INTS11 after PMA treatment
(FDR < 10%). Specifically, INTS11 PMA peaks replicated across all samples were used as reference for the INTS11 differential bind-
ing analysis. Similarly, INTS13 replicated across all samples were used as reference for the INTS13 differential binding analysis.
Subcellular fractionation
Subcellular fractionation was performed as described (Lai et al., 2015), with minor changes. Briefly, cells were resuspended in cold
cytoplasmic lysis buffer (10 mM Tris-HCl pH 7.5, 150 mMNaCl, 0.15%NP-40) using wide orifice tips, incubated on ice for 5 minutes,
layered onto cold sucrose buffer (10 Mm Tris-HCl pH 7.5, 150 Mm NaCl, 24% sucrose w/v) and centrifuge at 13,000 rpm for 10 mi-
nutes at 4C. Nuclei were gently resuspended in glycerol buffer (20 mM Tris pH 7.9, 75 mM NaCl, 0.5 mM EDTA, 50% glycerol,
0.85 mM DTT) using wide orifice tips, and same amount of nuclei lysis buffer (20 mM HEPES pH 7.6, 7.5 mM MgCl2, 0.2 mM
EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40, 1 mM DTT) was added. After a brief incubation for 1 minute on ice, chromatin was isolated
by centrifugation at 14,000 rpm for 2 minutes at 4C. Chromatin-bound RNA was isolated with Trizol protocol and miRNeasy kit
(QIAGEN).
RNA-seq sample processing
Samples from different conditions were processed together to prevent batch effects. Total RNA and chromatin-bound RNA were
extracted using ZymoDirect-Zol RNAminiprep Kit (Zymo research) andmiRNeasy kit with Trizol protocol and in-columnDNase treat-
ment (QIAGEN), respectively. Quality of total RNA was assessed by the RNA Integrity Number (RIN) using Agilent Bioanalyzer. All
retained RNA samples had a RIN > 8.
1 mg of total or chromatin-bound RNA were depleted of ribosomal RNA using the NEBNext rRNA depletion kit (New England Bio-
labs). rRNA-depleted RNA was purified with the miRNEasy kit (QIAGEN) and used to produce barcoded RNA sequencing libraries
using the NEBNext Ultra Directional RNA Library Prep kit (New England Biolabs), and sequenced on Illumina NextSeq 500, producing
75bp SE reads.
RNA-seq analyses
Reads were aligned to hg19 using STAR v2.5 (Dobin et al., 2013), in 2-pass mode with the following parameters:–quantMode
TranscriptomeSAM–outFilterMultimapNmax 10–outFilterMismatchNmax 10–outFilterMismatchNoverLmax 0.3–alignIntronMin
21–alignIntronMax 0–alignMatesGapMax 0–alignSJoverhangMin 5–runThreadN 12–twopassMode Basic–twopass1readsN
60000000–sjdbOverhang 100. We filtered bam files based on alignment quality (q = 10) using Samtools v0.1.19 (Li et al., 2009).
We used the latest annotations obtained from Ensembl to build reference indexes for the STAR alignment. FeatureCounts (Liao
et al., 2014) was used to count reads mapping to each gene. RSEM (Li and Dewey, 2011) was instead used to obtain FPKM (Frag-
ments Per Kilobase of exon per Million fragments mapped). We analyzed differential gene expression levels using read counts,
normalized by feature length with DESeq2 (Love et al., 2014), with the following model: design = condition, where condition indi-
cates either CTRL or PMA.e6 Molecular Cell 71, 103–116.e1–e7, July 5, 2018
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using R v3.3.1.
DATA AND SOFTWARE AVAILABILITY
The accession number for the total RNA-seq, chromatin RNA-seq and ChIP-seq data reported in this paper is GEO: GSE106359.
Figures were made with the package ggplot2 (Wickham, 2009). BEDtools v2.25.0 (Quinlan and Hall, 2010) was used for genomic
analyses.Molecular Cell 71, 103–116.e1–e7, July 5, 2018 e7
